New study tracks how eating behaviors vary with age, sex and body weight
Eating behavior varies with age and body weight. A University of Oulu study found that emotional and uncontrolled…
Novo’s CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
Novo NVO announced top-line results from two phase III studies evaluating once-weekly CagriSema, its investigational fixed-dose combination of…
Digital companion apps help secure long-term habits during GLP-1 therapy
Glucagon-like peptide-1 (GLP-1) medications have revolutionized weight management, yet high dropout rates and rapid weight regain remain significant…
Study identifies three distinct BMI trajectories among people with type 2 diabetes
A recent study by the University of Eastern Finland identified three distinct body mass index (BMI) trajectories among…
What 720,000 adults reveal about artificial sweeteners and diabetes risk
Data from more than 720,000 adults suggest that long-term consumption of artificial sweeteners may not be metabolically neutral,…
Serena Williams Defends GLP-1 Weight-Loss Drug Use: What Doctors Want You To Know
Tennis legend Serena Williams is speaking openly about her decision to use a GLP-1 weight-loss medication, adding her…
Protein craze can lead to better health if done right
It’s a question that Dr. Travis Wilkes gets asked every day by patients. It is something that Dr.…
Blood ketone threshold may help predict weight loss success
Researchers identify a practical blood ketone threshold linked to greater short-term weight loss, offering new insight into how…
Could GLP-1 Drugs Reduce Breast Cancer Risk?
GLP-1 medications are best known for their use in obesity and diabetes treatment, but new research suggests they may have potential in cancer prevention. As reported by The…
Canada approves generic version of Wegovy for weight loss
FILE – A dosage of Wegovy, March 1, 2024 in Front Royal, Va. (AP Photo/Amanda Andrade-Rhoades, File) –…
Most ‘GLP-1 Nonresponders’ Never Get a Fair Shot
I see this pattern every week. A patient is 12 weeks into semaglutide therapy. They’ve lost 2%-3% of…
Regulators issue warning on ads for unlicensed weight loss drugs – Chemist+Druggist
Regulators issue warning on ads for unlicensed weight loss drugs Chemist+DruggistNovo Nordisk moves to launch Wegovy tablet in China ScandasiaWhat…